The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Bliss GVS Pharma Limited stock forecast from 0 analysts, the average analyst target price for Bliss GVS Pharma Limited is not available over the next 12 months. Bliss GVS Pharma Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bliss GVS Pharma Limited is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Bliss GVS Pharma Limited’s stock price was INR 128.65. Bliss GVS Pharma Limited’s stock price has changed by +2.71% over the past week, +18.70% over the past month and +31.14% over the last year.
No recent analyst target price found for Bliss GVS Pharma Limited
No recent average analyst rating found for Bliss GVS Pharma Limited
Company Overview Bliss GVS Pharma Limited
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, soaps, sprays, and vaginal washes. In addition, the company offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India. Address: 102, Hyde Park, Mumbai, India, 400072 Read Less
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drop...Read More
Frequently Asked Questions About Bliss GVS Pharma Limited (BLISSGVS:NSE) Stock
Stock Target Advisor's fundamental analysis for Bliss GVS Pharma Limited's stock is Slightly Bullish .
BLISSGVS:NSE stock's dividend yield is 0.39%.
Our analysis grades BLISSGVS:NSE stock's dividend yield at F. This means that BLISSGVS:NSE stock's dividend yield is above 53% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this BLISSGVS:NSE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BLISSGVS:NSE's stock to indicate what its average analyst target is.
BLISSGVS:NSE stock's Price/Earning ratio is 16.82.
Our analysis grades BLISSGVS:NSE stock's Price / Earning ratio at B. This means that BLISSGVS:NSE stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this BLISSGVS:NSE may be undervalued for its sector.
The last closing price of BLISSGVS:NSE's stock was INR 128.65.
The most recent market capitalization for BLISSGVS:NSE is INR 13.79B.
Unfortunately we do not have enough analyst data on BLISSGVS:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bliss GVS Pharma Limited's stock.
As per our most recent records Bliss GVS Pharma Limited has 831 Employees.
Bliss GVS Pharma Limited's registered address is 102, Hyde Park, Mumbai, India, 400072.
You can get more information about it from Bliss GVS Pharma Limited's website at https://www.blissgvs.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bliss GVS Pharma Limited (BLISSGVS:NSE) Stock
Stock Target Advisor's fundamental analysis for Bliss GVS Pharma Limited's stock is Slightly Bullish .
BLISSGVS:NSE stock's dividend yield is 0.39%.
Our analysis grades BLISSGVS:NSE stock's dividend yield at F. This means that BLISSGVS:NSE stock's dividend yield is above 53% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this BLISSGVS:NSE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BLISSGVS:NSE's stock to indicate what its average analyst target is.
BLISSGVS:NSE stock's Price/Earning ratio is 16.82.
Our analysis grades BLISSGVS:NSE stock's Price / Earning ratio at B. This means that BLISSGVS:NSE stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this BLISSGVS:NSE may be undervalued for its sector.
The last closing price of BLISSGVS:NSE's stock was INR 128.65.
The most recent market capitalization for BLISSGVS:NSE is INR 13.79B.
Unfortunately we do not have enough analyst data on BLISSGVS:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bliss GVS Pharma Limited's stock.
As per our most recent records Bliss GVS Pharma Limited has 831 Employees.
Bliss GVS Pharma Limited's registered address is 102, Hyde Park, Mumbai, India, 400072.
You can get more information about it from Bliss GVS Pharma Limited's website at https://www.blissgvs.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BLISSGVS:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
